Clinical Trial Update: Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study of sunitinib in patients with advanced or inoperable fibrolamellar hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Hepatocellular Carcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED